The agreement includes an option to Merck for exclusive worldwide licenses for such peptides – on a peptide by peptide basis – covering the development and commercialization of therapeutic products.
Alex Kotzer, president and CEO of Compugen, said: “We are very pleased that our first collaboration based on this capability is with Merck, one of the world’s leading research-based pharmaceutical companies.”